XBI 240913 101.50P (XBI240913P101500) Stock Options, News & Quotes

US OptionsDetailed Quotes

XBI240913P101500

Watchlist

0.51
-1.56-75.36%

15min DelayClose Sep 13 16:00 ET

1.58High0.51Low

Intraday

5D
Daily

News

These four companies that are about to debut on the US stock market are worth focusing on. They may reverse the downturn in Biotech IPOs.
BioAge and Bicara hope to reverse the recent trend of obstacles in biotech companies' IPO in the US stock market; The binary nature of drug development has kept some investors away from the biotech industry.
Zhitong FinanceSep 5 03:08 ET
Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue. -- Barrons.com
Dow JonesAug 30 21:40 ET
Morgan Stanley Stays Bullish on AI, Obesity, and Defense Focused Themes
Seeking AlphaAug 28 11:13 ET
Nvidia Earnings Will Affect ETFs, See 20 Funds That Traditionally Observe the Largest Moves
Seeking AlphaAug 28 09:15 ET
Healthcare Bankruptcies Slow After Peaking in 2023: Report
Seeking AlphaAug 24 11:25 ET
Small-cap and Mid-cap Health Care Has Room to Rally - Roth MKM
Seeking AlphaAug 19 15:07 ET

Comments

Bellaah

Sep 11 11:10

$SPDR S&P Biotech ETF (XBI.US)$ 95

Moomoo Learn

Sep 6 03:05

Columns Navigating the wave of lower interest rates

Given the strong market expectations for a Federal Reserve rate cut, as indicated by the CME data with a 57% chance for a 25-basis-point reduction and a 43% chance for a 50-basis-point cut in September, investors are poised to reconsider their strategies.
With the Fed's September meeting likely to deliver a rate decrease, the question arises: how should investors allocate assets during an interest rate cut cycle? Let's delve into the tactics and consid...

CPI hits 3-year low: How will it sway the Fed rate decision?

frankinglily

Aug 25 22:03

Argument:
The upcoming interest rate cuts are poised to benefit the biotech stock industry, setting the stage for strong performance in the coming quarters.
Reasons:
Cheaper Funding: Lower interest rates make it easier for biotech companies to access capital for research and development, accelerating their progress and growth potential.
Attractive Valuations: Biotech stocks are currently trading at attractive levels, offering investors an opportunity to capitalize on the sector's long-term pot...

Powell said it's time to cut: Will the market go wild?

DDDDDDDDDDD

Aug 19 11:35

$SPDR S&P Biotech ETF (XBI.US)$ EASY TO SHORT $Sunshine Biopharma (SBFM.US)$ in the RAIN

Meltyy

Aug 6 02:51

$XBI down 3% today and 5% since before last Friday’s jobs report.

$SPDR S&P Biotech ETF (XBI.US)$
» Is this a smid-cap biopharma buying opportunity? 🤔
Stock market sell-off, e.g., $NASDAQ, started late last week on weak jobs data
XBI/smid-cap biopharma were part of sell-off
But..
» Is this sell-off justified for smid-cap biopharma?
» Is this a buying opportunity for smid-cap biopharma?
💡 Lower economic/jobs data = more likely entering lowering interest rate cycle for Fed Reserve
Usually go...